Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

Phase 0 Completed 10 enrolled Benaroya Research Institute

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.

Timeline

Start: 2020-05-30
Primary completion: 2021-12-10
Completion: 2021-12-10

Outcome

Missed primary endpoint

paper At the completion of therapy, none of the individuals achieved the primary outcome of MMTT-stimulated C-peptide ≥ 0.02 ng/mL. PMID 38096190 ↗

Publications

Lord SM, Bahnson HT, Greenbaum CJ, Liljenquist DR, Virostko J, Speake C. Testing a new platform to screen disease-modifying therapy in type 1 diabetes. PLoS One. 2023 Dec 14;18(12):e0293268. doi: 10.1371/journal.pone.0293268. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verapamil	Other / unclassified	—	Oral